Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTRiumph: Eplontersen With ALXN2220 vs Eplontersen With Placebo in ATTR-CM
jRCT2031260175Suspended
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Randomised trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing Eplontersen + ALXN2220 with Eplontersen + Placebo (2 arms). Primary endpoint: CPET peak VO2 change from baseline at week 52. Started Jun 2026; status: suspended.
02
Drugs
eplontersencliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2031260175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260175.